Company Profile
Updated: 29-OCT-09Zeltia S.A.
International public company
Jose Abascal 2, Madrid, E-28003, Spain
()34 91 444 45 00, 34 91 593 29 54 fax, http://www.zeltia.com
Primary SIC: Pesticides & Agricultural Chems, Not Elsewhere Classified, Primary NAICS: Pesticide and Other Agricultural Chemical Manufacturing
Description: Manufacturing: Head of a Group of Companies with interests in research and development, manufacture, import, export, marketing and distribution of chemicals and their derivatives; pharmaceuticals including serums for human and veterinary use; insecticides for domestic, agricultural and industrial use
View this company profile - Now for a Limited Time, try Goliath Company Profiles
Free for 3 Days!
Zeltia Mulls Options Following EU Rejection Of Sarcoma Drug.
BIOWORLD Today; 11/4/2009; 1264 words; ...Evaluation Agency (EMEA) rejected Zeltia's registration dossier on six grounds...oxaliplatin registered in the U.S., it will be necessary to do more...a shareholder in or consultant to Zeltia or its U.S. partner, Johnson & Johnson, but...
Clinic Roundup.
BIOWORLD Today; 11/3/2009; 791 words; ...interferon plus ribavirin therapy is expected to begin by July. o Zeltia Group, of Madrid, Spain, said its Neuropharma subsidiary started...clinical trials of NP031112, its first molecule for Alzheimer's disease. The Phase I trial will consist of two stages, with...
Zeltia adds 36% in two sessions on approval of Yondelis.
ADP News Spain; 9/29/2009; 506 words; ...since Friday when the company's Yondelis drug was approved for sale in Europe. Zeltia's soft tissue sarcoma (STS) drug...of refractory ovarian cancer. Zeltia closed yesterday's session with a 1.04% rise to...
Zeltia stocks close 34.54% higher on Friday after approval of Yondelis.
ADP News Spain; 9/28/2009; 589 words; ...Spanish chemical and pharmaceutical group Zeltia (MCE:ZEL) closed 34.54% up at...11,643.80 points. The company's soft tissue sarcoma (STS) drug Yondelis...Nearly two months earlier, on July 15, Zeltia's shares plummeted 34% to EUR 3.14...
Zeltia SA, which makes drugs from sea creatures, gained the most in at least 18 years in Madrid trading last week after the European Medicines Agency backed its request to market Yondelis as a treatment for relapsed ovarian cancer.(Brief article)
MondayMorning; 9/28/2009; 1025 words; ...relapsed ovarian cancer. Zeltia should be allowed to...Johnson & Johnson's (New Brunswick NJ...Securities. "It's a very positive piece of news for Zeltia." Yondelis has already...squirts. PharmaMar, Zeltia's cancer research unit...
Recent News Articles
- Zeltia's 2008 sales jump 23% to $134M.
Pharma Marketletter - March 09, 2009 - Q4 2008 Zeltia, S.A. Earnings Conference Call - Final.(Broadcast transcript)
Fair Disclosure Wire - February 26, 2009 - Zeltia's 3rd-qtr sales jump 24% on Yondelis.(Financial report)
Pharma Marketletter - November 10, 2008 - Zeltia changes name of subsid to Noscira.(Neuropharma)(Brief article)
Pharma Marketletter - September 29, 2008
Why Purchase This Company Profile?
- Sales prospecting
- Competitive analysis
- Vendor & supplier evaluation
- Customer evaluation and analysis
- Strategic planning
